IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

SP, Hack; J, Spahn; M, Chen; AL, Cheng; A, Kaseb; M, Kudo; HC, Lee; A, Yopp; P, Chow; S, Qin

doi:10.2217/fon-2020-0162

Public

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

Shared by NobleBlocks on Apr 30, 2020 • 12:00 AM UTC

Authors:

Hack SP

Spahn J

Chen M

Abstract

Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoint...

Subject

Hepatocellular carcinoma

VEGF

PD-L1

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!